bit.bio Bags $25Mn in Series D Funding to Expand Human Cell Technology

The new funding comes after the company's Series C round earlier this year. Existing investor M&G Investments also took part in the latest round, along with Dr Jonathan Milner, the founder and former CEO of Abcam.

Dr Emma Pepperell, CEO of bit.bio, commented on the growing demand for human cell models: "The industry is reaching an inflection point in drug discovery. AI is changing the speed at which new medicines can be discovered, while the move towards animal testing alternatives is creating growing demand for models that better reflect human biology. What these fundamental shifts have in common is the need for vast quantities of consistent human cell models. Someone needs to be able to supply those cells at scale and our investors believe bit.bio is the company capable of achieving that aim."

bit.bio is working to solve these challenges through its own technology, called opti-ox™. This platform helps produce specific types of human cells in large quantities while keeping their quality consistent.

The technology helps researchers overcome problems such as differences between donor cells and limited cell supplies. It provides a more reliable source of human cells that scientists can use for research and testing.

The company's ioCells portfolio currently includes more than 50 types of human cells. These include cells that represent parts of the heart, liver and central nervous system.

Researchers use these cells for different purposes, including studying diseases, understanding how genes work, discovering new drugs and testing the safety of medicines.

With its manufacturing facilities already in place, bit.bio plans to use the new funding to develop more types of human cells and make them available to more researchers. The company also aims to meet growing demand, grow its business and support the development and testing of new medicines.

Read Also- JawBuddy Raises €818K Pre-Seed Funding to Help People Manage Jaw Pain